Gilead’s Sovaldi Has Unclear Cancer Benefit, German Agency Says
This article is for subscribers only.
Gilead Sciences Inc.’s hepatitis C drug Sovaldi offers a benefit for patients, though the extent to which it prevents liver cancer is unclear, according to Germany’s drug-review panel.
While data submitted by Foster City, California-based Gilead showed Sovaldi can clear the virus, there was no proof that the drug helped prevent deaths, the Institute for Quality and Efficiency in Health, or IQWiG, said in a statement today.